Latest news with #JamesFoster
Yahoo
06-08-2025
- Business
- Yahoo
Charles River raises profit forecast on growing demand for drug development services
(Reuters) -Charles River Laboratories on Wednesday raised its annual profit forecast, betting on growing demand for its drug discovery and development services from drugmakers, sending its shares up more than 4% in premarket trading. The Wilmington, Massachusetts-based contract drug developer raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, compared with its previous projection of $9.30 to $9.80. Contract research organizations, which reported quarterly results over the last month, have all posted better-than-expected profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing. Companies such as Danaher, Medpace "We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth," Charles River CEO James Foster said. The company now also expects its 2025 revenue to decline 0.5% to 2.5%, compared with its previous forecast of a 3.5% to 5.5% drop. Charles River's second-quarter revenue came in at $1.03 billion, surpassing Wall Street estimates of $985.1 million, according to data compiled by LSEG. The company reported quarterly profit of $3.12 per share on an adjusted basis, compared with analysts' average estimate of $2.50. Separately, Charles River also said that the U.S. Fish and Wildlife Service had cleared its non-human primate (NHP) shipments from late 2022 and early 2023 for legal entry into the United States. In 2023, the company suspended the shipment of NHPs from Cambodia as the Department of Justice and U.S. Fish and Wildlife Service investigated it over smuggling of wild long-tailed macaques to the U.S. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
06-08-2025
- Business
- Reuters
Charles River raises profit forecast on growing demand for drug development services
Aug 6 (Reuters) - Charles River Laboratories (CRL.N), opens new tab on Wednesday raised its annual profit forecast, betting on growing demand for its drug discovery and development services from drugmakers, sending its shares up more than 4% in premarket trading. The Wilmington, Massachusetts-based contract drug developer raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, compared with its previous projection of $9.30 to $9.80. Contract research organizations, which reported quarterly results over the last month, have all posted better-than-expected profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing. Companies such as Danaher (DHR.N), opens new tab, Medpace <MEDP.O, IQVIA (IQV.N), opens new tab, ICON (ICLR.O), opens new tab and Thermo Fisher (TMO.N), opens new tab have posted strong results, owing to steady demand from the industry for tools and services used in the development of novel medicines. "We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth," Charles River CEO James Foster said. The company now also expects its 2025 revenue to decline 0.5% to 2.5%, compared with its previous forecast of a 3.5% to 5.5% drop. Charles River's second-quarter revenue came in at $1.03 billion, surpassing Wall Street estimates of $985.1 million, according to data compiled by LSEG. The company reported quarterly profit of $3.12 per share on an adjusted basis, compared with analysts' average estimate of $2.50. Separately, Charles River also said that the U.S. Fish and Wildlife Service had cleared its non-human primate (NHP) shipments from late 2022 and early 2023 for legal entry into the United States. In 2023, the company suspended the shipment of NHPs from Cambodia as the Department of Justice and U.S. Fish and Wildlife Service investigated it over smuggling of wild long-tailed macaques to the U.S.
Yahoo
14-05-2025
- General
- Yahoo
Where has the blue plaque gone on Lower High Street?
SPECULATION has been swirling on social media after eagle-eyed historians noticed the blue plaque dedicated to a renowned Stourbridge ironmaster is currently missing. A plaque dedicated to James Foster, who manufactured the Stourbridge Lion Locomotive – the very first railroad steam locomotive to be operated in the United States – has been adorning the wall of his old house on Lower High Street, a building now home to several offices. However, questions have been arising over the past few days after the space where the plaque sits was spotted empty. James Foster used to live on Lower High Street (Image: Google Earth) Despite fears the plaque had been removed or, at worst, stolen, one of the businesses in the building has confirmed the plaque has only temporarily been removed while decoration works are carried out to the building's exterior. Janice Chatham from NPP Neuro Group said: 'We're carry out some decorating work outside, and we noticed that one of the screws holding up the plaque had completely corroded. 'While the work is carried out, we've taken the plaque down and, for the time being, covered the space with a sign directing people to the building's disabled access. 'This is only temporary, and the plaque will be put up again as soon as possible, as well as a permanent disabled access sign too. 'It's nice to know that so many people care about our local history and notice the plaque when they walk past.'
